Biofilm and DispersinB

Kane Biotech Announces Positive Results From an Independent Wound Care Study.

Kane Biotech Inc. (TSX VENTURE:KNE), a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms, is pleased to announce positive results from an in vitro study using a novel approach to treat chronic wound infections with a combination of DispersinB and lytic bacteriophage.

The study carried out by Dr. Randy Wolcott's team at the Southwest
Regional Wound Care Center in Lubbock, Texas, showed that the
combination of DispersinB with a bacteriophage mixture was very
effective against biofilm-embedded E.coli. More specifically, the
DispersinB and bacteriophage mixture showed almost 99% inhibition of
E.coli growth and proliferation as compared to only 9% inhibition by the
bacteriophage mixture alone over the four day period of treatment. While
DispersinB makes biofilm-embedded bacteria more susceptible to
bacteriophage by inhibiting or dispersing biofilms, lytic bacteriophage
invades bacterial cells and disrupts the metabolism of the bacteria. This
combination therapy could provide a new and highly effective method of
treating chronic wounds such as diabetic foot ulcers.

"DispersinB degrades the defences of the biofilm, providing a synergistic
effect when combined with bacteriophages. Our findings are very
encouraging as DispersinB may also enhance the effectiveness of a
number of antimicrobial agents in the treatment of chronic wounds"
stated Dr. Wolcott. "I believe that DispersinB will also prove effective
against other wound infection associated bacteria in combination with
other antimicrobials and we are continuing our studies in this area."

"DispersinB is one of our lead technologies to prevent and disperse
biofilms and is proving to have very broad applications in the medical
field. This study adds further evidence to the growing knowledge base
on the value of our technology", stated Gord Froehlich, President and
CEO of Kane Biotech.

Chronic wounds are a serious debilitating complication of vascular
disease, diabetes and prolonged immobility and are a huge unmet clinical
need that costs the US health care system $20 billion per year. The
current global market for wound care management technology is
estimated at US$4.5 billon per year.

"Our DispersinB technology prevents and removes biofilms while the
bacteriophages and antimicrobial agents offer broad spectrum microbial
control. As a naturally occurring non-antibiotic antibiofilm enzyme,
DispersinB is a compelling technology for clinical settings", added Mr.
Froehlich.

About Dr. Randy Wolcott

Randall Wolcott, M.D., P.A., is the founder and medical director of the
Southwest Regional Wound Care Center in Lubbock, Texas. The focus
of Dr. Wolcott's clinical practice and research is wound healing. He is an
expert in biofilm-based chronic wound management and was
instrumental in initiating the research on chronic wounds at the Center
for Biofilm Engineering (CBE) Bozeman, MT. Dr. Wolcott, CBE and the
University of Washington received a $2.9 million grant from the National
Institutes of Health (NIH, USA) in 2006 to find new ways to heal chronic
wounds.

About the Southwest Regional Wound Care Center

The Southwest Regional Wound Care Center, located in Lubbock, Texas,
is dedicated to healing wounds. As a leader in treating hard to heal
wounds, everything the Center does is carefully designed to nurture,
always putting the patient first. The Center specializes in wound healing
using a biofilm-based wound care approach and treats up to 100
patients per day. The medical staff includes a physician, physician
assistants, nurses, social workers, physical therapists, licensed
vocational nurses (LVNs), certified hyperbaric oxygen technicians and
clinical technicians.

To see the full article and research notes, please visit Kane Biotech